Hypidone

Hypidone (developmental code name YL-0919) is an investigational serotonergic antidepressant which is under development for the treatment of major depressive disorder.[1][2][3][4][5] It acts as a serotonin reuptake inhibitor, 5-HT1A receptor partial agonist, and 5-HT6 receptor full agonist.[1][5] It is used as the hydrochloride salt.[2][5] As of January 2021, hypidone is in phase 2 clinical trials for major depressive disorder.[1]

Hypidone
Clinical data
Other namesYL-0919; YL0919
Identifiers
  • 1-[(1-benzyl-4-hydroxypiperidin-4-yl)methyl]pyridin-2-one
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H22N2O2
Molar mass298.386 g·mol−1
3D model (JSmol)
  • C1CN(CCC1(CN2C=CC=CC2=O)O)CC3=CC=CC=C3
  • InChI=1S/C18H22N2O2/c21-17-8-4-5-11-20(17)15-18(22)9-12-19(13-10-18)14-16-6-2-1-3-7-16/h1-8,11,22H,9-10,12-15H2
  • Key:BGMVOROUOUVVRV-UHFFFAOYSA-N

See also

References
  1. "Hypidone hydrochloride - Shanghai Synergy Pharmaceutical Sciences - AdisInsight". adisinsight.springer.com. Retrieved 2021-10-09.
  2. Zhang LM, Wang XY, Zhao N, Wang YL, Hu XX, Ran YH, Liu YQ, Zhang YZ, Yang RF, Li YF (May 2017). "Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HT1A agonist". 174 (9): 769–780. doi:10.1111/bph.13675. PMC 5386994. PMID 27882537. {{cite journal}}: Cite journal requires |journal= (help)
  3. Chen XF, Jin ZL, Gong Y, Zhao N, Wang XY, Ran YH, Zhang YZ, Zhang LM, Li YF (August 2018). "5-HT6 receptor agonist and memory-enhancing properties of hypidone hydrochloride (YL-0), a novel 5-HT1A receptor partial agonist and SSRI". Neuropharmacology. 138: 1–9. doi:10.1016/j.neuropharm.2018.05.027. PMID 29805118. S2CID 44125.
  4. Yin YY, Tian CY, Fang XX, Shang C, Zhang LM, Xu Q, Li YF (2020). "The Faster-Onset Antidepressant Effects of Hypidone Hydrochloride (YL-0919) in Monkeys Subjected to Chronic Unpredictable Stress". Front Pharmacol. 11: 586879. doi:10.3389/fphar.2020.586879. PMC 7725870. PMID 33324217.
  5. Liu WG, Zhang LM, Yao JQ, Yin YY, Zhang XY, Li YF, Cao JB (2021). "Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT1A Receptor Partial Agonist/5-HT6 Receptor Full Agonist". Front Pharmacol. 12: 625547. doi:10.3389/fphar.2021.625547. PMC 7902863. PMID 33643051.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.